According to a recent LinkedIn post from ViGenCell(바이젠셀), the company is participating in the ChinaBio Partnering Forum 2026 in Shanghai, focusing on expanding global partnering and licensing discussions for its cell and gene therapy pipeline. The post directs readers to a Korean press release for further details, indicating a structured effort to communicate partnering opportunities and strategic direction to potential collaborators.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The same post also highlights domestic and international media coverage of ViGenCell’s selection for an oral presentation at ASCO, including articles in The Korea Herald and the Financial Times. This visibility at a major oncology conference may enhance the company’s credibility in oncology-focused cell therapy, potentially supporting future licensing deals, partnership negotiations, and valuation expectations in the biotech and biopharma investment community.